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report of a clinical case and discussion on the
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Background: Cardiovascular magnetic resonance (CMR) with late gadolinium enhancement (LGE) imaging is
increasingly used to assess myocardial involvement in patients with Fabry disease, an X linked lipid storage disorder.
However, it is often proposed as an optional tool. A different cardiomyopathic disease progression between male and
female patients was hypothesised in previous studies, as in female myocardial fibrosis was found without left ventricular
(LV) hypertrophy, while myocardial fibrosis was always detected in association to LV hypertrophy in men.
Case presentation: A male Caucasian patient, 19 years old, diagnosed through a family-based molecular screening,
presented with LGE of the LV inferolateral wall evidenced at the CMR, without LV hypertrophy, or other clinical signs
of the disease.
Conclusion: This is the first report of cardiac fibrosis as the first sign of organ involvement in a male patient with
Fabry disease. This finding stresses the importance of performing CMR with LGE imaging for the initial staging and
monitoring of Fabry patients of both genders.
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Fabry disease is an X linked lysosomal storage disorder,
characterised by the deficient activity of the enzyme
α-galactosidase A, involved in the catabolism of gly-
cosphingolipids. This enzymatic defect results in the
accumulation of globotrialosylceramide within the cells,
particularly in cardiomyocytes, kidney, neural and vas-
cular endothelial cells, causing a progressive systemic
disease, which can lead to severe cardiac, renal, and cere-
brovascular complications [1]. Heterozygous females may
become as severely affected as males, although generally
at a later age [2]. In males the diagnosis is made by the
demonstration of α-gal deficiency in leukocytes and/or* Correspondence: sechi.annalisa@aoud.sanita.fvg.it
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unless otherwise stated.by the identification of pathogenic mutations in the
α-galactosidase gene (GLA, Xq22.1 region). In heterozy-
gous females, the enzymatic activity is not a reliable test,
due to random X-chromosome inactivation, rendering
DNA sequencing of the GLA gene the only reliable test for
the diagnosis confirmation in females. Once the GLA mu-
tation is identified, a screening within the family is indi-
cated in order to detect Fabry patients at an early stage [3],
when the disease seems to be more responsive to the spe-
cific enzyme replacement therapy (ERT) [4,5].
Cardiac involvement in Fabry disease includes arrhyth-
mias, ischemia, and cardiomyopathy and is associated
with increased morbidity and mortality in both male and
female patients [6]. Left ventricular (LV) hypertrophy
is considered the most common cardiologic finding [1].
Studies using cardiovascular magnetic resonance (CMR),
demonstrated that myocardial fibrosis, detected with latetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ural history of Fabry disease [7,8]. A recent cardio-
vascular imaging research on patients with Fabry disease,
showed a different cardiomyopathic involvement be-
tween male and female subjects: myocardial fibrosis
was always detected in association to LV hypertrophy
in men, while in females LGE was found even with normal
LV thickness [9].
As far as we know, this is the first report of cardiac
fibrosis as the first sign of organ involvement in a male
patient with Fabry disease.
Case presentation
A 19 years old boy was diagnosed with Fabry disease
through a family-based molecular screening, demon-
strating the presence of the R112H mutation in the GLA
gene. The diagnosis was further confirmed by the assess-
ment of enzymatic α-gal activity in leucocytes, which
resulted undetectable. Subsequently, he was admitted for
a global screening of disease clinical manifestations al-
though, at the time of diagnosis, he appeared completely
asymptomatic. His neurological and general examin-
ation, including cardiac auscultation, were unremarkable.
Biochemical tests (including 24 h microalbuminuria, pro-
teinuria and creatinine clearance), ophthalmologic as-
sessment, audiometry, pulmonary function tests, brain
and kidney magnetic resonance imaging did not show
any abnormality.
For the cardiac assessment he underwent first trans-
thoracic echocardiography, 12-lead electrocardiogram,
24-hour Holter recording, and bicycle stress test, all
resulting normal. Finally CMR with LGE imaging wasFigure 1 Cine and late gadolinium enhancement (LGE) CMR images o
precession sequence) CMR of short-axis (A) and 4-chamber (B) view showin
short-TI inversion-recovery fast spin-echo image of short-axis (C), 4-chambe
oedema. Panel F and G: contrast-enhanced inversion recovery gradient echo
the inferolateral wall with intramyocardial distribution (black arrow).performed; cine images (steady-state free precession) con-
firmed normal biventricular size and systolic function and
normal LV wall thickness (Figure 1A-B). No signal alter-
ations were detected on black-blood T1-weighted fast
spin-echo imaging and T2-weighted short TI inversion
recovery imaging (Figure 1C-E). Conversely, delayed en-
hancement imaging performed 10 minutes after injection
of Gadolium chelate contrast agent showed LGE of the
LV inferolateral wall with intramyocardial distribution
(Figure 1F-G). Of note, despite the absence of LV wall
motion abnormalities, feature-tracking analysis of cine
LV mid short-axis slice demonstrated reduced circumfer-
ential strain of the mid inferolateral wall (Figure 2).
Considering the male gender and the evidence of a
cardiac involvement, ERT treatment with recombinant
agalsidase alfa was started and administered intraven-
ously at the standard dosage of 0.2 mg/kg every other
week, without side effects. After 12 months of ERT car-
diological assessment including ECG, echocardiography
and CMR was repeated, showing no changes com-
pared to baseline (Figure 3); in particular LGE of the
LV inferolateral wall was still observed and unchanged
(Figure 3C-D).
Discussion
To our knowledge this is the first case reported so far,
which demonstrates the presence of LGE without LV
hypertrophy in a male affected by Fabry disease. Never-
theless, few CMR studies on Fabry patients have been
published until now. Indeed, in the international consen-
sus guidelines for Fabry disease, CMR is not included
among the recommended exams for the basal evaluationf the patient at baseline. Panel A and B: cine (steady-state free
g normal left ventricular wall thickness. Panel C, D and E: T2-weighted
r (D) and 3-chamber (E) view showing the absence of myocardial
image of short-axis (F) and 3-chamber (G) view showing LGE involving
Figure 2 Feature-tracking analysis. 2D Cardiac Performance Analysis Software (TomTec, Munich, Germany) was used to measure LV deformation
directly from cine CMR images (left panel). Feature-tracking analysis of cine LV mid short-axis slice demonstrated reduced circumferential strain of the
mid infero-lateral wall (pale blue line in the right panel).
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is not routinely performed [3,10,11].
In 2003 Moon and colleagues first reported CMR find-
ings in 18 male and 8 female patients with Fabry disease,
describing LGE in 9/18 males and 4/8 females. In 92% of
patients LGE occurred in the basal inferolateral wall,
with intramyocardial pattern. Two male patients with se-
vere LV hypertrophy had additional hyperenhancementFigure 3 Cine and late gadolinium enhancement (LGE) CMR
images of the patient, acquired after 12 months of ERT. Panel A
and B: cine (steady-state free precession sequence) CMR of short-axis
(A) and 4-chamber (B) view showing normal left ventricular wall
thickness. Panel C and D: contrast-enhanced inversion recovery gradient
echo image of short-axis (C) and 3-chamber (D) view showing LGE
involving the inferolateral wall with intramyocardial distribution
(black arrow), without significant changes from baseline examination
(Figure 1).in other myocardial sites. One female patient with LGE
had normal echocardiography [7].
In 2005 Weidemann and colleagues published a fur-
ther cardiac imaging study (using echocardiography,
strain rate imaging, and CMR) on 39 Fabry patients,
finding LGE in 12 of them (2 females and 10 males).
The inferolateral wall was confirmed as the typical LGE
location. All subjects, of both genders, had also LV
hypertrophy associated to LGE. All patients with LGE
had severely reduced radial and longitudinal function.
One patient with LGE died and histology confirmed fi-
brotic tissue in the inferolateral wall [8].
Recently, Niemann and colleagues published a large
CMR study, including 104 patients (58 females and 46
males) with genetically proven Fabry disease. LGE was
detected in 33% (n.19) of females and 48% (n.22) of
males. Sixty-eight % of these patients showed LGE in the
typical basal lateral location. Interestingly, 10 female pa-
tients without LV hypertrophy already presented LGE
positive segments, while LGE was not found in male
patients with LV thickness < 12 mm. Based on these re-
sults, the authors concluded that cardiomyopathy dis-
ease progression in Fabry disease differs between male
and female patients, only the latter showing fibrosis be-
fore hypertrophy [9].
On the contrary, our findings suggest that LGE can be
the first sign of cardiomyopathy even in male patients. It
is possible that LGE without LV hypertrophy has never
been found in males affected by Fabry disease because
only few patients have been studied with CMR until now
and most of them, being older than the patient re-
ported here (i.e. 46 ± 12 years in the study by Niemann),
had already developed both LV hypertrophy and fibrosis
at the time of the study. Since the proposed temporal
sequence of Fabry cardiomyopathy (increasing wall
thickness➔ replacement fibrosis) [8] is not always present
even in men, further pathogenetic studies are needed to
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development of hypertrophy in Fabry patients.
It is worth noting that our case, as well as 11 females
already reported [9,7], did not manifest any cardiac
symptom and had no wall motion abnormalities at the
echocardiography but showed LGE at the CMR, suggest-
ing that conventional assessment is not sufficient to de-
tect subtle cardiac abnormalities. Our patient and 7/10
female with isolated LGE described by Niemann et al
were diagnosed by genetic screening within the family
after the identification of a proband. Taking into account
these results, we should stress the importance to per-
form CMR to stage and monitor Fabry cardiomyopathy,
after diagnosis in both genders, even in apparently
asymptomatic patients with a normal echocardiogram.
CMR can be also fundamental in the diagnostic process
of patients evaluated for cardiomyopathy, as LGE in the
midmyocardium of the basal-inferolateral wall seems to
be characteristic of Fabry disease [12]. It should be ac-
knowledged that LGE in the midmyocardium of the
basal-inferolateral wall can also be observed in other
pathologies, including previous myocarditis [13]. In our
patient, however, history of symptoms suggestive of re-
mote myocarditis was negative. Moreover, recently, non
contrast T1 mapping by CMR has been proposed by
Thompson et al. as a tool to distinguish LV hypertrophy
do to Fabry disease, from other causes. In fact, septal T1
was found to be lower in Fabry patients compared with
healthy controls and patients with similar patterns of LV
hypertrophy, probably reflecting glycosphingolipids accu-
mulation. The authors concluded that reduced non-
contrast myocardial T1 values are the most sensitive and
specific cardiovascular MRI parameter in patients with
Fabry disease irrespective of sex and LV morphology and
function [14]. Unfortunately this technique is not avail-
able at our hospital.
Of note, feature-tracking analysis of cine LV mid
short-axis slice demonstrated reduced circumferential
strain of myocardial segment presenting LGE, despite
the absence of LV wall motion abnormalities; this under-
lines the utility of myocardial deformation imaging tech-
niques (including speckle-tracking echocardiography,
tagged-CMR and feature-tracking CMR) for the identifica-
tion of subtle changes of myocardial function which cannot
be detected with conventional measures such as qualitative
wall motion assessment [15].
Cardiac fibrosis is considered a negative prognostic
factor towards ERT response in patients who already
show LV hypertrophy [16], and an increased amount of
LGE (from 0.5 to 7.1%) after 12 months of ERT has been
reported [17]. To date, no data are available on the effect
of ERT in patients with isolated cardiac fibrosis. Our pa-
tient did not show any LGE change after one year of
ERT treatment at the CMR assessment. Therefore, it ispossible to hypothesise that cardiac fibrosis accompanied
by LV hypertrophy would be a sign of a late stage cardiac
disease, which rapidly progresses despite ERT. Instead,
when cardiac fibrosis appears early in a non-hypertrophic
myocardium, it may have a more favourable response to
treatment. However, we do not know what would have
been the natural course of fibrosis in our patient without
ERT. Further CMR studies on large cohorts and long term
follow up are needed to assess whether ERT initiated be-
fore the onset of LV hypertrophy can prevent the cardio-
myopathy progression.
Conclusions
The development of myocardial fibrosis does not neces-
sarily require myocardial hypertrophy in both male and
female patients with Fabry disease. CMR should be in-
cluded in the routing diagnostic assessment and follow-
up monitoring of all Fabry patients.
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